Alliance Pharma PLC Director Shareholding (9808Q)
June 23 2015 - 8:30AM
UK Regulatory
TIDMAPH
RNS Number : 9808Q
Alliance Pharma PLC
23 June 2015
For immediate release 23 June 2015
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Director Shareholding
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical
company, was notified on 23 June 2015 that on 23 June 2015, Lynette
Booley, spouse of Anthony Booley, an-Executive Director of the
Company, sold 1,000,000 ordinary shares of 1 pence in the Company
("Ordinary Shares") at a price of 37.0 pence per share, and Anthony
Booley sold 1,155,000 Ordinary Shares on the same date at the same
price.
Following this transaction, Mr Booley's total beneficial
interest in the Company is 2,055,723 Ordinary Shares, representing
approximately 0.78% of the Company's issued share capital.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
/ Jane Glover
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: David
Poutney
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has a strong track record of acquiring the rights to
established niche products and owns or licenses the rights to more
than 60 pharmaceutical products and continues to explore
opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSFJMTTMBBTBAA
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024
